Urinary Tract Infection
Return to Library
|
Free Urinary Tract Infection Articles |
|
|
|
|
Research from Northwestern University, Medical Department broadens understanding of urinary tract infection
2009 AUG 3 - (NewsRx.com) -- According to a study from the United States, "Uropathogenic Escherichia coli are the leading cause of urinary tract infection. We recently demonstrated that deletion of the O antigen ligase gene, waaL, from the uropathogenic E. coliisolate NU14 results in a strain that stimulates enhanced urothelial cytokine secretion." "Because enhanced innate immune responses are of interest in vaccine development, we examined the therapeutic potential of NU14 Delta waaL as a vaccine for urinary tract infection. NU14 DwaaL stimulated enhanced interleukin-6 secretion by mouse macrophages, compared with secretion by the wild type. Mice vaccinated via instillation into the bladder developed protective responses that prevented persistent colonization after bladder challenge with NU14, yet NU14 DwaaL failed to persistently colonize the mouse bladder. Inoculation with the vaccine strain protected mice against challenge with a broad range of clinical uropathogenic E. coli isolates and produced immunity that lasted >= 8 weeks," wrote B.K. Billips and colleagues, Northwestern University, Medical Department. The researchers concluded: "Therefore, NU14 DwaaL is a candidate live-attenuated vaccine for the treatment and prevention of acute and recurrent urinary tract infection by caused by uropathogenic E. coli." Billips and colleagues published the results of their research in the Journal of Infectious Diseases (A Live-Attenuated Vaccine for the Treatment of Urinary Tract Infection by Uropathogenic Escherichia coli. Journal of Infectious Diseases, 2009;200(2):263-272). For additional information, contact D.J. Klumpp, Northwestern University, Feinberg School Medical, Dept. of Urology, Tarry 16-703, 303 E Chicago Avenue, Chicago, IL 60611, USA. The publisher of the Journal of Infectious Diseases can be contacted at: University Chicago Press, 1427 E 60th St., Chicago, IL 60637-2954, USA. Keywords: United States, Chicago, Biotechnology, Enzyme Research, Escherichia coli, Immunization, Ligase, Medical Device, Therapy, Treatment, Urinary Tract Infection, Urology, Vaccination, Vaccine Development, Vaccines, Northwestern University, Medical Department. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
